Pharma BD Deal Intelligence
A $15M Liverpool CDMO bolt-on that quietly survived four corporate parents and sold for $118.7M in 2021 — a solid financial outcome, but the asset was never core and ultimately exited the lineage entirely.
Full analysis, sources & comparables →FierceBiotech characterized the Arrow deal as Watson's bid for global generic scale, with the Eden Biodesign stake as a forward bet on biosimilars rather than…
Watson Pharmaceuticals acquires Eden Biodesign, giving the generics maker entry into biopharmaceutical contract development and manufacturing services.
Watson completes acquisition of Eden Biodesign, adding biopharmaceutical development and manufacturing capabilities to its Global Brands Division, including…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Watson acquired Eden Biodesign as part of broader Arrow Group transactions, providing biologic manufacturing capability for generic biologicals strategy.
A $15M Liverpool CDMO bolt-on that quietly survived four corporate parents and sold for $118.7M in 2021 — a solid financial outcome, but the asset was never core and ultimately exited the lineage entirely.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited (this deal) | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2010 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Other deals